Project reMIND: Treatment Methods beyond the Blood-Brain Barrier (BBB)

In June 2022, Micronit joined the reMIND project. In reMIND, the University of Twente and companies Demcon, Locsense, Micronit and Scinus Cell Expansion are working on four different but complementary technologies that contribute to the development of therapies for neurodegenerative diseases such as Alzheimer’s disease.

The blood-brain barrier forms the fysical boundary between the blood and the brain. This barrier is highly selective in allowing substances to pass through to the brain. Because of this BBB, it is very difficult to administer medication in the brain for the treatment of neurological disorders. The reMIND consortium has simulated a BBB on a chip to investigate whether it is possible to ‘open up’ the BBB with the help of ultrasonic triggering and microbubbles in order to be able to administer regenerative therapies or medication directly into the brain.

Main goal of the project

The goal of reMIND is to develop and industrialize these technologies that contribute to the development of new treatment methods beyond the blood-brain barrier (BBB).

Funding

This project has received funding from OP Oost, European Regional Development Fund.